Circio Holding ASA (”Circio” or ”the Company”) announced, on the 27th of May 2026, a research collaboration with AaviGen GmbH (”AaviGen”), a Heidelberg-based biotechnology company developing precision gene therapies for cardiac diseases. The collaboration aims to enable low-dose, high-precision AAV gene therapy for genetic and chronic heart conditions by combining circVec with AaviGen’s proprietary heart-targeted capsids, and will proceed in three stages: production of novel AAVs that combine AaviGen’s capsids with Circio’s circVec expression cassette, in vitro characterization, and in vivo validation of AAV biodistribution and gene expression profiles. No financial terms are disclosed.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.